InMed Pharmaceuticals (INM) Short term Debt (2021 - 2022)
InMed Pharmaceuticals (INM) posted quarterly Short term Debt of $29312.0 for Q1 2022, down 50.0% quarter-over-quarter from $58624.0 in Q4 2021.
InMed Pharmaceuticals (INM) Short term Debt (2021 - 2022) Analysis & Trends
InMed Pharmaceuticals' Short term Debt history runs 2 years deep, the most recent figure standing at $29312.0 for Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 29,312.00 |
| Dec 31, 2021 | 58,624.00 |